A pioneering study by researchers at the University of Tehran has revealed the therapeutic potential of the cytokine Interleukin-17 (IL-17a) in treating colorectal cancer (CRC). The findings mark a major advancement in immunotherapy approaches and open new avenues for targeted treatment strategies. This is reported by
IRNA, a partner of TV BRICS.
Based on a six-year analysis of 2,900 CRC patients, the research demonstrated that controlled elevation of IL-17a levels in blood and within the tumour microenvironment induces apoptosis (programmed cell death) and inhibits metastasis-related molecules. These mechanisms significantly improve the immune system’s…